Twice weekly rapid COVID-19 testing to be available to everyone in England
Access to twice weekly, free, regular, rapid coronavirus (COVID-19) testing from 9 April for everyone in England, the Government has announced. Everyone in England,...
Oxford COVID vaccine team wins funding to develop jab to prevent gonorrhea
The Jenner Institute, part of the University of Oxford, UK, has been awarded up to US$2 million to develop a novel vaccine to prevent...
EU approval for Novartis’ treatment of relapsing forms of MS
The European Commission has approved Novartis’ Kesimpta® (ofatumumab) for the treatment of (RMS) in adults with active disease defined by clinical or imaging features. Kesimpta...
GSK to support manufacture of Novavax’ COVID-19 vaccine
GlaxoSmithKline (GSK) has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million...
New lateral flow device distribution service announced for pharmacies
A new advanced service – the NHS community pharmacy COVID-19 lateral flow device distribution service – has been added to the NHS Community Pharmacy Contractual Framework (CPCF). The service,...
UK Health Security Agency launched to deal with future threats
A new UK Health Security Agency (UKHSA) has launched to plan for, prevent and respond to future external health threats such as infectious diseases. The...
AstraZeneca releases updated US trial data on COVID-19 vaccine
AstraZeneca has released updated information about its COVID-19 vaccine following concern expressed by the Data and Safety Monitoring Board (DSMB) about initial data from...
MSD’s pembrolizumab added to NHSE COVID interim treatment list
MSD has reached an agreement with NHS England to make pembrolizumab available in England for eligible patients with metastatic MSI-H/dMMR colorectal cancer as an...
Alzheimer’s Research UK partners with Boston University on wearable tech project
UK charity Alzheimer’s Research UK has partnered with Boston University for the development of a wearable to detect early Alzheimer’s and other neurodegenerative diseases...
Positive Phase III study results for prostate cancer patients from Novartis
Novartis has reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy...
Latest articles
Antibiotic Research UK launches small research grants programme
Antibiotic Research UK (ANTRUK), the world’s first charity tackling bacterial antibiotic resistance, has just launched its largest grants programme to date, the 2021 Small...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
New COVID-19 test reduces testing time from 30 minutes to five
University of Birmingham researchers have invented a COVID-19 test that reduces testing time from 30 minutes to under five, whilst still delivering accurate results. The...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...